In the BioHarmony Drug Report Database

"Preview" Icon

Cannabidiol

Epidiolex, Epidyolex (cannabidiol) is a small molecule pharmaceutical. Cannabidiol was first approved as Epidiolex on 2018-09-28. It is used to treat anxiety, lennox gastaut syndrome, myoclonic epilepsies, and pain in the USA. It has been approved in Europe to treat lennox gastaut syndrome and myoclonic epilepsies. It is known to target N-arachidonyl glycine receptor, transient receptor potential cation channel subfamily V member 2, G-protein coupled receptor 55, transient receptor potential cation channel subfamily M member 8, transient receptor potential cation channel subfamily A member 1, transient receptor potential cation channel subfamily V member 3, and cannabinoid receptor 1. Epidiolex’s patents are valid until 2035-10-14 (FDA).

 

Trade Name

 

Epidyolex
 

Common Name

 

cannabidiol
 

ChEMBL ID

 

CHEMBL190461
 

Indication

 

anxiety, lennox gastaut syndrome, myoclonic epilepsies, pain
 

Drug Class

 

Cannabinol derivatives

Image (chem structure or protein)

Cannabidiol structure rendering